Carnero-Fernández M, Pineda J R, Lite-Alvarez J M
Servicio de Medicina Interna, Hospital Meixoeiro, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, España.
Gastroenterol Hepatol. 2006 May;29(5):297-8. doi: 10.1157/13087470.
We describe the case of a 20-year-old man who developed severe thrombocytopenia and hemorrhagic complications 5 months after beginning pegylated interferon therapy for chronic hepatitis C. Interferon therapy was stopped and platelets were transfused, but the platelet count did not increase until treatment with immunoglobulins and intravenous corticosteroids was started. Therefore, we believe this would suggest a possible autoimmune mechanism for the development of thrombocytopenia with interferon therapy. Mild reduction in platelets count is a common adverse effect of this drug. Nevertheless, severe decreases and secondary serious hemorrhagic complications have been infrequently described in the literature.
我们描述了一名20岁男性的病例,该患者在开始聚乙二醇化干扰素治疗慢性丙型肝炎5个月后出现严重血小板减少和出血并发症。停止干扰素治疗并输注血小板,但在开始使用免疫球蛋白和静脉注射皮质类固醇治疗之前,血小板计数并未增加。因此,我们认为这可能提示干扰素治疗导致血小板减少的一种自身免疫机制。血小板计数轻度降低是该药物常见的不良反应。然而,文献中很少描述严重降低及继发的严重出血并发症。